Senti Bio reports positive initial clinical data from Phase 1 trial of SENTI-202
Senti Bio (SNTI) reports positive initial clinical data on SENTI-202, an off-the-shelf cell therapy for hematologic malignancies. Results show promising remission rates in AML patients with well-tolerated treatment. Dose escalation is ongoing for further evaluation.